Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
September 26 2022 - 8:35AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial
biopharmaceutical company working to develop and launch the first
FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, today announced it will present at
Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022
in Chicago, Illinois.
As part of the event, Russ Trenary, President
and Chief Executive Officer will present as a part of the Retina
Showcase, and Terry Dagnon, Chief Operations Officer will
participate in a panel presentation. Details for the presentations
are as follows:
Panel: Defining Clinically
Relevant Endpoints in Approval TrialsTime: 11:45
AM – 12:30 PM ETDiscussion Topic: Government,
academic, and industry experts offer perspectives on benchmarking
practices that accurately characterize the effectiveness of
treatments in clinical studies and meet regulatory
requirements.Company Participant: Terry Dagnon,
Chief Operations OfficerCompany Presentation:
Retina ShowcasesTime: 2:46 PM – 2:51 PM ET
Presenter: Russ Trenary, President and Chief
Executive Officer
Eyecelerator is a partnership between the
American Academy of Ophthalmology (AAO) and the American Society of
Cataract and Refractive Surgery (ASCRS) that aims to connect
entrepreneurs, investors, companies and physicians to advance
ophthalmic innovation through live conferences, virtual programming
and a next-generation networking platform. For more information,
visit Eyecelerator @ AAO.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg), an investigational therapy, as the first
FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, including wet AMD, DME and BRVO. Outlook
Therapeutics has submitted its Biologics License Application (BLA)
to the U.S. Food and Drug Administration (FDA) for ONS-5010 to
treat wet AMD. The submission is supported by Outlook Therapeutics’
wet AMD registration clinical program, which consists of three
clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010
ophthalmic bevacizumab is approved, Outlook Therapeutics expects to
commercialize it as the first and only FDA-approved ophthalmic
formulation of bevacizumab for use in treating retinal diseases in
the United States, United Kingdom, Europe, Japan and other markets.
For more information, please
visit www.outlooktherapeutics.com.
CONTACTS:Media Inquiries:Anna
ArmyAccount SupervisorLaVoie Health ScienceT:
617-351-0246aarmy@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024